BioMed X Institute launches Rapid Antiviral Response Platform for pandemics

▴ biomedx-institute-launches-rapid-antiviral-response-platform-for-covid19
BioMed X is an independent research institute located on the campus of the University of Heidelberg in Germany.

BioMed X, an independent research institute that identifies big biomedical research challenges and provides innovative solutions by combining global crowdsourcing with local incubation, announces the launch of its new Rapid Antiviral Response Platform (RAR).

In response to the devastating COVID-19 pandemic, BioMed X strives to develop an arsenal of ultrafast new antiviral drug discovery, development and mass-manufacturing tools that will allow to go from the identification of a new viral pathogen to 10,000 doses of a safe and potent new medication in less than 6 months.

Christian Tidona, Founder & Managing Director of the BioMed X Institute and initiator of the RAR Platform:“SARS-CoV-2 is a serious threat for global public health and the global economy. Current drug discovery, development and mass-manufacturing processes are far too slow to respond to a viral pandemic like COVID-19. To avoid a lockdown of the global economy in the future, we need completely new technologies which are at least ten times faster than the present state-of-the-art. This is what our RAR Platform intends to deliver.”

The RAR Platform will be developed using BioMed X’s successful new innovation model which brings together the best early-career biomedical scientists from top universities and research institutions all over the world to work on solutions for big research challenges in the fields of biomedicine, molecular biology, cell biology and diagnostics. Until now, each research project at BioMed X has been sponsored by an industry partner such as Merck, Boehringer Ingelheim, Janssen, AbbVie, and Roche.

“Our new initiative is aimed at all pharmaceutical companies, foundations, public health organizations, government agencies and healthcare funds world-wide who would like to pioneer this field of research and who want to make a real impact for society. At the end of the five-year research and development project, all members of the RAR Consortium will receive equal world-wide rights to use all components of the resulting Rapid Antiviral Response Platform for any commercial or non-commercial purpose.” Tidona continues.

The RAR Platform will consist of eight project modules, each focusing on a different viral target space across a wide variety of virus genera infecting humans or animals. Each organization who joins the RAR Consortium can freely choose to support one of these eight project modules.

BioMed X is an independent research institute located on the campus of the University of Heidelberg in Germany. Together with their partners, they identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world’s brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. BioMed X,  combines the best of two worlds – academia and industry – and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.

Tags : #BioMedX #AntiviralResponsePlatform #Pandemic #Germany

About the Author

Team Medicircle

Related Stories

Loading Please wait...

Trending Now

India Covid Vaccine Rollout : A detailed state wise update Jan 19,2021January 19, 2021
Lakshadweep reports first Covid-19 case January 19, 2021
Country's COVID-19 recovery rate reaches 96.66 per cent; more than 3, 81000 people vaccinated so farJanuary 19, 2021
Biden stays the travel ban for passengers from UK, Brazil and EU countriesJanuary 19, 2021
US faces 400000 lakh deaths due to CoronavirusJanuary 19, 2021
Sirnaomics announces first patient dosed In phase 2a study of STP705January 18, 2021
Andhra Pradesh: 332 locations identified for rollout of COVID-19 vaccinationJanuary 18, 2021
COVID-19 Vaccination begins in Kargil at District HospitalJanuary 18, 2021
Jharkhand: Covid vaccination drive underway at all 49 centresJanuary 18, 2021
Higher coffee intake may be linked to lower prostate cancer riskJanuary 18, 2021
Vaccination drive against Covid-19 being carried out four days a week in West BengalJanuary 18, 2021
Short term low carbohydrate diet linked to remission of type 2 diabetesJanuary 18, 2021
Enhertu approved in the US for the treatment of patients with previously treated HER2-positive advanced gastric cancerJanuary 18, 2021
How important is nutrition for health?January 18, 2021
GSK presents positive efficacy data of dostarlimab in mismatch repair-deficient solid cancers at ASCO Gastrointestinal Cancers SymposiumJanuary 18, 2021
Avian Influenza confirmed in crow samples from Haridwar, Lansdowne forest range of UttarakhandJanuary 18, 2021
National COVID-19 recovery rate improves to 96.59 per centJanuary 18, 2021
Over 5, 48, 000 COVID samples tested in country in last 24 hoursJanuary 18, 2021
India's vibrant Biotechnology sector ; A failsafe investment optionJanuary 18, 2021
Total 447 adverse events reported during COVID vaccination: Health Ministry January 18, 2021